BRNS VS CDXC Stock Comparison

PerformanceEarningsVolatilityAnalyst Price TargetsSentimentTechnicalsProfit
PerformanceEarningsVolatilityAnalyst Price TargetsSentimentTechnicalsProfit

Performance

BRNS
10/100

BRNS returned -42.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CDXC
10/100

CDXC returned -23.46% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Earnings

BRNS
100/100

BRNS has missed earnings 1 times in the last 20 quarters.

CDXC
10/100

CDXC has missed earnings 6 times in the last 20 quarters.

Volatility

BRNS
50/100

BRNS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

CDXC
46/100

CDXC has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Analyst Price Targets

BRNS

"Analyst Price Targets" not found for BRNS

CDXC
88/100

2 analysts offer 12-month price targets for CDXC. Together, they have an average target of 0, the most optimistic target put CDXC at 0 within 12-months and the most pessimistic has CDXC at 0.

Sentiment

BRNS

"Sentiment" not found for BRNS

CDXC
73/100

CDXC had a bullish sentiment score of 72.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.80 posts, 1.24 comments, and 2.68 likes per day.

Technicals

BRNS

"Technicals" not found for BRNS

CDXC
10/100

CDXC receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Profit

BRNS

"Profit" not found for BRNS

CDXC
10/100

Out of the last 20 quarters, CDXC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Barinthus Biotherapeutics plc American Depositary Shares Summary

Nasdaq / BRNS
Healthcare
Biotechnology
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

ChromaDex Corporation Summary

Nasdaq / CDXC
Healthcare
Biotechnology
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.